Market Overview

Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation

Share:
Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA), a biotechnology company developing GalXC RNAi platforms for various diseases, has seen its stock soar 140 percent over the past six months. But a combination of good news and bad news should leave investors on the sidelines, according to B. Riley FBR.

The Analyst

B Riley FBR's Madhu Kumar initiated coverage of Dicerna Pharmaceuticals' stock with a Neutral rating and $10 price target.

The Thesis

Dicerna's stock is a story of good news and bad news, Kumar said in a Tuesday report. On the positive side, Dicerna's GalXC RNAi platform boasts "multiple shots on goal" in both orphan and non-orphan diseases. The company's lead asset, DCR-PHXC for the treatment of primary hyperoxaluria, is currently undergoing Phase 1 trials. DCR-HBVS for the treatment of hepatitis B has guided an investigational new drug designation for the fourth quarter.

"Overall, Dicerna has a liver-directed RNAi platform with multiple clinical entrants expected in 2018," Kumar said. 

On the bearish side, the analyst is "cautious" on the company's PH RNAi program, as early, striking safety and efficacy data from a competing drug, Alnylam's lumasiran, implies Dicerna has "little margin for error" in its study, the analyst said.

This could limit upside in Dicerna's stock ahead of the initial Phase 1 DCR-PHXC results in the bottom half of 2018, according to B Riley FBR. 

Price Action

Shares of Dicerna Pharmaceuticals were down 8.2 percent to $9.18 at the time of publication Wednesday.

Related Links:

Chardan: After Dicerna Pharma's 370% Run, Wait For Better Entry Point

Exclusive: Dicerna CEO Talks Goals For 2017, Competitors And Prospects Under Trump

Latest Ratings for DRNA

DateFirmActionFromTo
Aug 2020SVB LeerinkMaintainsOutperform
Aug 2020HC Wainwright & Co.MaintainsBuy
May 2020RBC CapitalInitiates Coverage OnOutperform

View More Analyst Ratings for DRNA
View the Latest Analyst Ratings

 

Related Articles (DRNA)

View Comments and Join the Discussion!

Posted-In: B Riley FBR biotechnologyAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
NKLADeutsche BankMaintains29.0
WHRDeutsche BankMaintains153.0
TREXDeutsche BankMaintains72.0
IBPDeutsche BankMaintains110.0
GPNLoop CapitalInitiates Coverage On199.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com